Hong Kong · Delayed Price · Currency is HKD Genor Biopharma Holdings Company Description
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally.
The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid tumours.
It also develops GB226, which is in Phase III clinical trial; GB261, which is in Phase I/II clinical trial for NHL; and GB263T that is in Phase I/II clinical trial for NSCLC.
In addition, the company develops GB221, which is in Phase III clinical trial for HER2+ 1L/2L+ mBC; GB223 that is in Phase I clinical trial for GCTB, PMO; GB241 that is in Phase III clinical trial for 1L DLBCL; and GB251, which is in Phase I clinical trial for HER2+ 1L/2L+ mBC.
Further, the company’s product candidates that are in pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for cancer treatment.
The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021.
The company was founded in 2007 and is headquartered in Shanghai, China.
| Country | Cayman Islands |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Feng Guo |
Contact Details
Address: Building 6 Shanghai, 201203 China | |
| Phone | 86 21 6169 0700 |
| Website | genorbio.com |
Stock Details
| Ticker Symbol | 6998 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG3871A1004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Feng Guo Ph.D. | Chief Executive Officer |
| Chengyi Weng | Chief Financial Officer and Executive Director |
| Qibin Liang | Chief Technology Officer |
| Xiaojing Zhu | Vice President of Compliance and Administration |
| Tong Li M.D. | Chief Medical Officer |
| Tak Wai Ip | Company Secretary |
| Jun Lin | Vice President of Quality Analysis |
| Qingtang Duan | General Manager of Yuxi Genor |